La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Baxter International Gestione
Gestione criteri di controllo 2/4
Baxter International's Il CEO è Joe Almeida, nominato in Jan2016, e ha un mandato di 8.58 anni. la retribuzione annua totale è $ 13.79M, composta da 9.4% di stipendio e 90.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.11% delle azioni della società, per un valore di $ 20.59M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 4.5 anni.
Informazioni chiave
Joe Almeida
Amministratore delegato
US$13.8m
Compenso totale
| Percentuale dello stipendio del CEO | 9.4% |
| Mandato del CEO | 8.6yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 1.8yrs |
| Durata media del Consiglio di amministrazione | 4.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Baxter- Reiterating Our Buy Rating After A Promising Q2
Aug 07Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.29
Aug 07
Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
Jul 23Baxter: Why Investors Should Take Advantage Of The Low Valuation
Jul 16Little Excitement Around Baxter International Inc.'s (NYSE:BAX) Revenues
Jul 12Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 30Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
May 14Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 08Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
Nov 27Is Baxter International (NYSE:BAX) A Risky Investment?
Oct 27Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital
Sep 21Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Aug 23Dividend Challengers Review: Baxter International
Aug 14Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29
Jul 25Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet
Jul 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture
Jun 07Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 19Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 05Baxter International Inc.'s (NYSE:BAX) Intrinsic Value Is Potentially 26% Above Its Share Price
Apr 24Is Baxter International (NYSE:BAX) Using Too Much Debt?
Apr 03Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 18Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$157m |
| Mar 31 2024 | n/a | n/a | -US$38m |
| Dec 31 2023 | US$14m | US$1m | -US$76m |
| Sep 30 2023 | n/a | n/a | US$225m |
| Jun 30 2023 | n/a | n/a | -US$3b |
| Mar 31 2023 | n/a | n/a | -US$3b |
| Dec 31 2022 | US$14m | US$1m | -US$3b |
| Sep 30 2022 | n/a | n/a | -US$3b |
| Jun 30 2022 | n/a | n/a | US$876m |
| Mar 31 2022 | n/a | n/a | US$992m |
| Dec 31 2021 | US$16m | US$1m | US$1b |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$1b |
| Mar 31 2021 | n/a | n/a | US$1b |
| Dec 31 2020 | US$16m | US$1m | US$1b |
| Sep 30 2020 | n/a | n/a | US$911m |
| Jun 30 2020 | n/a | n/a | US$924m |
| Mar 31 2020 | n/a | n/a | US$991m |
| Dec 31 2019 | US$14m | US$1m | US$1b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$16m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$1b |
| Jun 30 2018 | n/a | n/a | US$795m |
| Mar 31 2018 | n/a | n/a | US$840m |
| Dec 31 2017 | US$15m | US$1m | US$609m |
Compensazione vs Mercato: La retribuzione totale di Joe ($USD 13.79M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 13.21M ).
Compensazione vs guadagni: La retribuzione di Joe è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Joe Almeida (62 yo)
8.6yrs
Mandato
US$13,786,671
Compensazione
Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board | 8.6yrs | US$13.79m | 0.11% $ 21.6m | |
| Executive VP & CFO | less than a year | US$5.37m | 0% $ 0 | |
| Executive VP & Group President of Medical Products and Therapies | 1.4yrs | US$4.86m | 0.031% $ 6.1m | |
| Executive VP & Group President of Pharmaceuticals | 2.1yrs | US$3.87m | 0.0016% $ 301.0k | |
| Executive VP & Group President of Kidney Care | 1.2yrs | US$9.64m | 0.0046% $ 881.8k | |
| Senior VP and Chief Medical & Scientific Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Information Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Executive VP & General Counsel | 2.3yrs | US$5.66m | 0.0018% $ 349.2k | |
| Senior Vice President | no data | Nessun dato | Nessun dato | |
| Executive VP & Chief Human Resources Officer | 7.3yrs | US$4.14m | 0.037% $ 7.1m | |
| Executive VP & Chief Supply Chain Officer | 4.6yrs | Nessun dato | 0.0030% $ 576.9k |
1.8yrs
Durata media
54yo
Età media
Gestione esperta: Il team dirigenziale di BAX non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board | 8.6yrs | US$13.79m | 0.11% $ 21.6m | |
| Independent Director | less than a year | US$197.82k | 0.0018% $ 343.4k | |
| Chairman Emeritus | 8.6yrs | US$17.88m | Nessun dato | |
| Independent Director | 2.3yrs | US$349.64k | 0.0026% $ 501.7k | |
| Independent Director | 7.5yrs | US$373.98k | 0.0055% $ 1.1m | |
| Independent Director | 5.5yrs | US$364.98k | 0.0042% $ 808.5k | |
| Independent Director | 2.7yrs | US$363.00k | 0.0028% $ 540.3k | |
| Independent Director | 7.6yrs | US$367.31k | 0.0044% $ 852.8k | |
| Lead Independent Director | 2.3yrs | US$382.31k | 0.0026% $ 501.7k | |
| Independent Director | 3.5yrs | US$357.00k | 0.0032% $ 615.5k | |
| Independent Director | 1.2yrs | US$226.35k | 0.0019% $ 372.4k | |
| Independent Director | 5.5yrs | US$352.98k | Nessun dato |
4.5yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BAX sono considerati esperti (durata media dell'incarico 4.5 anni).